Ibrutinib, Bendamustine, Rituximab Combination for Relapsed and Refractory Aggressive B Cell Lymphoma - Interim Analysis of Phase II Clinical Trial

被引：4
|
作者：
Kedmi, Meirav [1 ,2 ,3 ]
Ribakovsy, Elena [1 ]
Benjamini, Ohad [1 ,2 ]
Schiby, Ginette [2 ,4 ]
Barshack, Iris [2 ,4 ]
Raskin, Stephen P. [5 ]
Eshet, Yael [5 ]
Mehr, Ramit [3 ]
Bitansky, Guy [2 ]
Nagler, Arnon [2 ,6 ]
Avigdor, Abraham [1 ,2 ]
机构：
[1] Chaim Sheba Med Ctr, Div Hematol & Bone Marrow Transplantat, Ramat Gan, Israel
[2] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
[3] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Ramat Gan, Israel
[4] Chaim Sheba Med Ctr, Dept Pathol, Ramat Gan, Israel
[5] Chaim Sheba Med Ctr, Dept Radiol & Nucl Med, Ramat Gan, Israel
[6] Chaim Sheba Med Ctr, Dept Hematol, Tel Hashomer, Israel
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-111658
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4186
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B-Cell Lymphoma
    Kedmi, Meirav
    Ribakovsy, Elena
    Benjamini, Ohad
    Schiby, Ginette
    Barshack, Iris
    Raskin, Stephen
    Eshet, Yael
    Mehr, Ramit
    Horowitz, Netanel
    Gurion, Ronit
    Goldschmidt, Neta
    Perry, Chava
    Levi, Itai
    Aviv, Ariel
    Herzog-Tzarfati, Katrin
    Nagler, Arnon
    Avigdor, Abraham
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (06)
  • [2] Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma
    Grieve, Clare
    Joseph, Ashlee
    Drullinsky, Pamela
    Zelenetz, Andrew D.
    Hamlin, Paul
    Kumar, Anita
    LEUKEMIA & LYMPHOMA, 2024, 65 (02) : 235 - 241
  • [3] A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma
    Qingyuan Zhang
    Rong Tao
    Zhenyu Li
    Haiyi Guo
    Meng Ji
    Lu Zhang
    Jane Huang
    Fu Lina
    Jinhua Zhong
    Jianfeng Zhou
    LEUKEMIA & LYMPHOMA, 2022, 63 (10) : 2503 - 2506
  • [4] Ibrutinib and Rituximab Are an Efficacious and Safe Combination in Relapsed Mantle Cell Lymphoma: Preliminary Results from a Phase II Clinical Trial
    Wang, Michael
    Hagemeister, Fredrick
    Westin, Jason R.
    Fayad, Luis
    Samaniego, Felipe
    Turturro, Francesco
    Chen, Wendy
    Zhang, Liang
    Badillo, Maria
    DeLa Rosa, Maria
    Addison, Alicia
    Kwak, Larry W.
    Romaguera, Jorge E.
    BLOOD, 2014, 124 (21)
  • [5] The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia
    Hallek, Michael
    Kay, Neil E.
    Osterborg, Anders
    Chanan-Khan, Asher A.
    Mahler, Michelle
    Salman, Mariya
    Wan, Ying
    Sun, Steven
    Zhuang, Sen Hong
    Howes, Angela
    FUTURE ONCOLOGY, 2015, 11 (01) : 51 - 59
  • [6] Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma
    Ogura, Michinori
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Watanabe, Takashi
    Uchida, Toshiki
    Ohmachi, Ken
    Matsumoto, Yosuke
    Tobinai, Kensei
    CANCER SCIENCE, 2011, 102 (09) : 1687 - 1692
  • [7] Phase III trial of bendamustine plus rituximab for relapsed or refractory diffuse large B-cell lymphoma in Japan
    Kiguchi, Toru
    Terui, Yasuhito
    Izutsu, Koji
    Kameoka, Yoshihiro
    Hidaka, Michihiro
    Kato, Harumi
    Matsumura, Itaru
    Kuroda, Junya
    Ishizawa, Kenichi
    Ichikawa, Satoshi
    Ando, Kiyoshi
    Ogura, Michinori
    Tobinai, Kensei
    Fukushima, Koji
    Murayama, Kayoko
    ANNALS OF ONCOLOGY, 2021, 32 : S304 - S304
  • [8] Combination of acalabrutinib with lenalidomide and rituximab in relapsed/refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial
    Changhee Park
    Ho Sup Lee
    Ka-Won Kang
    Won-Sik Lee
    Young Rok Do
    Jae-Yong Kwak
    Ho-Jin Shin
    Sung-Yong Kim
    Jun Ho Yi
    Sung-Nam Lim
    Jeong-Ok Lee
    Deok-Hwan Yang
    Hun Jang
    Byoungsan Choi
    Jiwoo Lim
    Choong Hyun Sun
    Ja Min Byun
    Sung-Soo Yoon
    Youngil Koh
    Nature Communications, 15
  • [9] Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I Trial
    Kambhampati, Swetha
    Fakhri, Bita
    Ai, Weiyun Z.
    Kaplan, Lawrence D.
    Tuscano, Joseph M.
    Wieduwilt, Matthew J.
    Sudhindra, Akshay
    Cavallone, Erika
    Reiner, Jesika
    Aoun, Charlie
    Castillo, Miguel
    Martinelli, Michelle
    Ta, Teresa
    Le, Diem
    Padilla, Michelle
    Crawford, Erika
    Andreadis, Charalambos B.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (03) : 139 - 146
  • [10] Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-cell non-Hodgkin lymphoma
    Dang, Nam H.
    Fayad, Luis
    McLaughlin, Peter
    Romaguara, Jorge E.
    Hagemeister, Fredrick
    Goy, Andre
    Neelapu, Sattva
    Samaniego, Felipe
    Walker, Pamela L.
    Wang, Michael
    Rodriguez, Maria A.
    Tong, Ann T.
    Pro, Barbara
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (04) : 502 - 505
12345